share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:擬議出售證券
美股SEC公告 ·  11/13 00:38

牛牛AI助理已提取核心訊息

Arcutis Biotherapeutics, Inc. Director Terrie Curran is set to sell 8,687 shares of common stock on 11/11/2024, with an aggregate market value of $94,238. The shares to be sold were acquired through restricted stock vests on two separate occasions, with 4,312 shares acquired on 06/01/2023 and an additional 4,375 shares on 05/31/2024. The company has not reported any other securities transactions by Curran in the past three months.
Arcutis Biotherapeutics, Inc. Director Terrie Curran is set to sell 8,687 shares of common stock on 11/11/2024, with an aggregate market value of $94,238. The shares to be sold were acquired through restricted stock vests on two separate occasions, with 4,312 shares acquired on 06/01/2023 and an additional 4,375 shares on 05/31/2024. The company has not reported any other securities transactions by Curran in the past three months.
Arcutis Biotherapeutics, Inc.董事Terrie Curran計劃於2024年11月11日賣出8,687股普通股,合計市值$94,238。待售股票是通過兩次受限股票解禁獲得的,其中4,312股是在2023年06/01獲得的,另外4,375股是在2024年05/31獲得的。該公司並未報告Curran在過去三個月內的任何其他證券交易。
Arcutis Biotherapeutics, Inc.董事Terrie Curran計劃於2024年11月11日賣出8,687股普通股,合計市值$94,238。待售股票是通過兩次受限股票解禁獲得的,其中4,312股是在2023年06/01獲得的,另外4,375股是在2024年05/31獲得的。該公司並未報告Curran在過去三個月內的任何其他證券交易。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。